PortfoliosLab logo
RXST vs. IDYA
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RXST and IDYA is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.4

Performance

RXST vs. IDYA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in RxSight, Inc. (RXST) and IDEAYA Biosciences, Inc. (IDYA). The values are adjusted to include any dividend payments, if applicable.

-100.00%0.00%100.00%200.00%300.00%NovemberDecember2025FebruaryMarchApril
-6.56%
-22.45%
RXST
IDYA

Key characteristics

Sharpe Ratio

RXST:

-1.17

IDYA:

-0.99

Sortino Ratio

RXST:

-2.03

IDYA:

-1.57

Omega Ratio

RXST:

0.69

IDYA:

0.83

Calmar Ratio

RXST:

-0.93

IDYA:

-0.74

Martin Ratio

RXST:

-1.90

IDYA:

-1.44

Ulcer Index

RXST:

38.35%

IDYA:

35.51%

Daily Std Dev

RXST:

62.22%

IDYA:

51.86%

Max Drawdown

RXST:

-78.10%

IDYA:

-74.64%

Current Drawdown

RXST:

-76.75%

IDYA:

-59.69%

Fundamentals

Market Cap

RXST:

$607.27M

IDYA:

$1.66B

EPS

RXST:

-$0.71

IDYA:

-$3.36

PS Ratio

RXST:

4.34

IDYA:

237.60

PB Ratio

RXST:

2.13

IDYA:

1.58

Total Revenue (TTM)

RXST:

$120.51M

IDYA:

$7.00M

Gross Profit (TTM)

RXST:

$78.26M

IDYA:

$5.90M

EBITDA (TTM)

RXST:

-$15.81M

IDYA:

-$274.69M

Returns By Period

In the year-to-date period, RXST achieves a -56.52% return, which is significantly lower than IDYA's -26.07% return.


RXST

YTD

-56.52%

1M

-43.94%

6M

-70.33%

1Y

-71.67%

5Y*

N/A

10Y*

N/A

IDYA

YTD

-26.07%

1M

9.01%

6M

-35.15%

1Y

-52.43%

5Y*

29.44%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RXST vs. IDYA — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXST
The Risk-Adjusted Performance Rank of RXST is 22
Overall Rank
The Sharpe Ratio Rank of RXST is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of RXST is 22
Sortino Ratio Rank
The Omega Ratio Rank of RXST is 22
Omega Ratio Rank
The Calmar Ratio Rank of RXST is 22
Calmar Ratio Rank
The Martin Ratio Rank of RXST is 22
Martin Ratio Rank

IDYA
The Risk-Adjusted Performance Rank of IDYA is 77
Overall Rank
The Sharpe Ratio Rank of IDYA is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of IDYA is 55
Sortino Ratio Rank
The Omega Ratio Rank of IDYA is 99
Omega Ratio Rank
The Calmar Ratio Rank of IDYA is 88
Calmar Ratio Rank
The Martin Ratio Rank of IDYA is 1010
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RXST vs. IDYA - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for RxSight, Inc. (RXST) and IDEAYA Biosciences, Inc. (IDYA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for RXST, currently valued at -1.17, compared to the broader market-2.00-1.000.001.002.003.00
RXST: -1.17
IDYA: -0.99
The chart of Sortino ratio for RXST, currently valued at -2.03, compared to the broader market-6.00-4.00-2.000.002.004.00
RXST: -2.03
IDYA: -1.57
The chart of Omega ratio for RXST, currently valued at 0.69, compared to the broader market0.501.001.502.00
RXST: 0.69
IDYA: 0.83
The chart of Calmar ratio for RXST, currently valued at -0.93, compared to the broader market0.001.002.003.004.005.00
RXST: -0.93
IDYA: -0.74
The chart of Martin ratio for RXST, currently valued at -1.90, compared to the broader market-5.000.005.0010.0015.0020.00
RXST: -1.90
IDYA: -1.44

The current RXST Sharpe Ratio is -1.17, which is comparable to the IDYA Sharpe Ratio of -0.99. The chart below compares the historical Sharpe Ratios of RXST and IDYA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
-1.17
-0.99
RXST
IDYA

Dividends

RXST vs. IDYA - Dividend Comparison

Neither RXST nor IDYA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RXST vs. IDYA - Drawdown Comparison

The maximum RXST drawdown since its inception was -78.10%, roughly equal to the maximum IDYA drawdown of -74.64%. Use the drawdown chart below to compare losses from any high point for RXST and IDYA. For additional features, visit the drawdowns tool.


-80.00%-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%NovemberDecember2025FebruaryMarchApril
-76.75%
-59.69%
RXST
IDYA

Volatility

RXST vs. IDYA - Volatility Comparison

RxSight, Inc. (RXST) has a higher volatility of 51.25% compared to IDEAYA Biosciences, Inc. (IDYA) at 23.46%. This indicates that RXST's price experiences larger fluctuations and is considered to be riskier than IDYA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%NovemberDecember2025FebruaryMarchApril
51.25%
23.46%
RXST
IDYA

Financials

RXST vs. IDYA - Financials Comparison

This section allows you to compare key financial metrics between RxSight, Inc. and IDEAYA Biosciences, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items